Comparison of Lifestyle Markers Between Women With and Without Polycystic Ovary Syndrome

February 8, 2024 updated by: Cornell University

Baseline Assessment of Dietary Intake and Physical Activity in Women With Polycystic Ovary Syndrome (PCOS)

The purpose of the study is to identify lifestyle factors associated with PCOS and understand how diet and activity levels impact features of PCOS. The secondary aim is to examine psychosocial factors (e.g., health beliefs) of women with PCOS.

Study Overview

Detailed Description

Polycystic ovary syndrome (PCOS) is an endocrine disorder that affects 6-12% of reproductive-aged women within the general population. Currently, there is limited knowledge on the current lifestyles of women with PCOS and the psychosocial factors associated with PCOS.

The researchers plan to examine potential lifestyle differences and psychosocial factors between PCOS and healthy women. The Research Team is also interested in the relationships between biological markers and lifestyle endpoints in women with and without PCOS. Previous literature has shown there are biological marker differences between those with and without PCOS. By examining these relationships, researchers may further understand whether PCOS status is associated with lifestyle parameters.

To accomplish these objectives, 360 women (120 women with PCOS, 120 women without PCOS and with normal menstrual cycles, and 120 women without PCOS and with irregular menstrual cycles) will be included in this study. An equal number of lean and overweight/obese women will be recruited within each group based on body mass index (BMI; Lean = 18 - 24 kg/m2 and overweight/obese ≥ 25 kg/m2). Women will be included in the PCOS group if they have a confirmed PCOS diagnosis from their primary care provider. Participants will complete a food frequency questionnaire, a sleep questionnaire, and a physical activity questionnaire. A researcher may also provide participants with a waist-worn accelerometer to monitor physical activity and a wrist-worn accelerometer to monitor sleep for a week. Ultrasound scans of the ovaries will be assessed and the following metabolic parameters will be assessed: (1) 75-gram oral glucose tolerance test; (2) dual X-ray absorptiometry (DXA) scan; (3) vitals and anthropometry assessment to measure waist and hip circumference, height, weight, blood pressure, and heart rate; (4) fasting blood tests to detect androgens (i.e., total testosterone, androstenedione, free androgen index); and (5) an (optional) subcutaneous fat biopsy. Women with and without PCOS will also be asked to complete a questionnaire that will assess the psychosocial factors (e.g., health beliefs). This can be conducted online, in person, or through phone.

Study Type

Observational

Enrollment (Actual)

126

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • New York
      • Ithaca, New York, United States, 14853
        • Human Metabolic Research Unit, Cornell University
      • Rochester, New York, United States, 14623
        • Strong Fertility Center
      • Rochester, New York, United States, 14642
        • CRC at University of Rochester Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 48 years (Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

New York State. Must be between 18-48 years, with a BMI of 18 kg/m2 or higher.

Description

Inclusion Criteria:

  • Between 18 and 48 years
  • BMI ≥ 18 kg/m2
  • If ≥ 21 years old, must have completed a pelvic exam in the past 2 years
  • In PCOS if: Confirmed PCOS diagnosis from their primary care provider

Exclusion Criteria:

  • Use of oral contraceptives, fertility medications, or any drugs known to influence reproductive function
  • Pregnant or breastfeeding

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Retrospective

Cohorts and Interventions

Group / Cohort
Women with a past diagnosis of PCOS
We aim to recruit 120 women with a past diagnosis of PCOS. An equal number of lean and overweight/obese women will be recruited within this group based on body mass index (BMI; Lean = 18 - 24 kg/m2 and overweight/obese ≥ 25 kg/m2).
Women with a history of regular menstrual cycles
We aim to recruit 120 women with a history of regular menstrual cycles. An equal number of lean and overweight/obese women will be recruited within this group based on body mass index (BMI; Lean = 18 - 24 kg/m2 and overweight/obese ≥ 25 kg/m2).
Women with a history of irregular menstrual cycles
We aim to recruit 120 women with a history of irregular menstrual cycles, and no previous diagnosis of PCOS. An equal number of lean and overweight/obese women will be recruited within this group based on body mass index (BMI; Lean = 18 - 24 kg/m2 and overweight/obese ≥ 25 kg/m2).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Differences in diet between women with and without PCOS
Time Frame: 1 week
A food frequency questionnaire will be administered to assess diet composition for the last three months.
1 week

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Androgen concentrations
Time Frame: 1 day
Total testosterone, androstenedione and free androgen index concentrations in serum will be determined and compared across groups.
1 day
LH-FSH ratio
Time Frame: 1 day
The ratio of circulating LH to FSH concentrations in the serum will be determined for each participant and compared across groups
1 day
Menstrual Cycle Length
Time Frame: 1 day
Average menstrual cycle length as determined by self-reported history will be determined and compared across groups
1 day
Differences in exercise between women with and without PCOS
Time Frame: 1 week
An accelerometer will be administered to assess physical activity for 1 week.
1 week
Differences in psychosocial factors (e.g., health beliefs) of women with and without PCOS
Time Frame: 1-2 weeks
A questionnaire will be administered to assess psychosocial factors of women with PCOS.
1-2 weeks
Differences in sleep patterns between women with and without PCOS
Time Frame: 6 consecutive nights
A wrist-worn accelerometer will be administered to assess sleep patterns for 6 consecutive nights.
6 consecutive nights
Hirsutism Score
Time Frame: 1 day

Degree of hirsutism as judged by the Ferriman-Gallwey scale will be determined and compared across groups

Degree of hirsutism as judged by the Ferriman-Gallwey scale will be determined and compared across groups

1 day
Body Mass Index
Time Frame: 1 day
The ratio of weight to height will be determined and compared across groups.
1 day
Waist-to-Hip Ratio
Time Frame: 1 day
The ratio of waist circumference to hip circumference will be determined and compared across groups
1 day
Ovarian Volume
Time Frame: 1 day
The size of each ovary will be determined using ultrasonography for each participant during study participation and compared between groups.
1 day
Insulin Sensitivity
Time Frame: 1 day
Insulin sensitivity will be determined by administration of an oral glucose tolerance test and compared between groups.
1 day
Serum progesterone concentration
Time Frame: 1 day
The serum progesterone concentration will be determined during study participation, assessed in association with luteal dynamics and compared between groups.
1 day
Blood pressure
Time Frame: 1 day
Blood pressure will be determined and compared between groups.
1 day
Serum markers of metabolic syndrome
Time Frame: 1 day
Lipids, glucose and HbA1C concentrations will be determined and compared between groups.
1 day
Body fat distribution
Time Frame: 1 day
Percentage and distribution of fat and lean mass as assessed using DXA technology will be compared between groups.
1 day
Subcutaneous fat biopsy (optional)
Time Frame: 1 day
Subcutaneous fat cells, which represent important sites of reproductive hormone synthesis, will be assessed and compared across groups
1 day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Marla E. Lujan, PhD, Cornell University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2013

Primary Completion (Actual)

May 1, 2022

Study Completion (Actual)

May 1, 2022

Study Registration Dates

First Submitted

May 17, 2013

First Submitted That Met QC Criteria

May 20, 2013

First Posted (Estimated)

May 22, 2013

Study Record Updates

Last Update Posted (Estimated)

February 9, 2024

Last Update Submitted That Met QC Criteria

February 8, 2024

Last Verified

February 1, 2024

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Polycystic Ovary Syndrome

3
Subscribe